Skip to content
  • Home
  • Book Bag: 0 items (Full)
    • English
    • 日本語
    • 中文(简体)
    • 中文(繁體)
    • اللغة العربية
  • About
Advanced
  • P942: DREAMM-9: PHASE I STUDY...
  • Cite this
  • Text this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Add to Book Bag Remove from Book Bag
  • Permanent link

P942: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

Bibliographic Details
Published in:HemaSphere
Main Authors: S. Z. Usmani, M. Mielnik, Y. Koh, A. Alonso Alonso, X. Leleu, H. Quach, C.-K. Min, W. Janowski, A.-O. Abdallah, M. Garg, I. Sandhu, E. M. Ocio San Miguel, A. Oriol, P. Rodriquez-Otero, K. Ramasamy, K. Weisel, B. Besemer, M. Cavo, X. L. Zhou, M. C. Kaisermann, C. M. Bego Marques, D. Williams, F. Carreno, B. E. Kremer, I. V. Gupta, M. Hus
Format: Article
Language:English
Published: Wiley 2022-06-01
Online Access:http://journals.lww.com/10.1097/01.HS9.0000846636.06566.b4
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://journals.lww.com/10.1097/01.HS9.0000846636.06566.b4

Similar Items

  • P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA
    by: S Usmani, et al.
    Published: (2022-04-01)
  • P864: A PHASE 1 STUDY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH STANDARD OF CARE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF DREAMM-9
    by: Saad Z Usmani, et al.
    Published: (2023-08-01)
  • P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-4 STUDY
    by: A. Suvannasankha, et al.
    Published: (2022-06-01)
  • P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL
    by: A. Nooka, et al.
    Published: (2023-05-01)
  • Dreamm-2: single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma (rrmm), including subgroups with renal impairment (ri) and high-risk (hr) cytogenetics
    by: S. Lonial, et al.
    Published: (2020-09-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs